Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:

• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

• Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?

• How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?

Candrice Heath, MD, shares some highlights from the Pediatric Skin of Color Symposium about the treatment of acne in pediatric patients with skin of color, including:

• What is your personal approach to treating acne in patients with skin of color?

• Can you tell us about the approved and emerging therapies for treatment of acne in pediatric patients? Have any of them been studied in patient populations with skin of color?

• Can you explain why it is important to treat both acne and post-inflammatory hyperpigmentation, particular in patients of color?

• How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?

Latanya Benjamin, MD, shares some highlights from the Pediatric Skin of Color Symposium at MOPD about the treatment of atopic dermatitis in pediatric patients with skin of color, including:

• Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?

• What is your personal approach to treating AD in pediatric patients with skin of color?

• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

Amy McMichael, MD, Chair of the CME Symposium "Diversity in Derm Treatments: Skin of Color" at SBS 2021, leads a panel discussion with Valerie Callender, MD, and Seemal Desai, MD, to share clinical pearls and key takeaways about treatment of dermatologic conditions in patients with skin of color.

Glenn Speer, PhD, has been working with dermatologists to manage his psoriatic arthritis symptoms for over 20 years. In this video interview, Glenn tells his story, including:

• Can you share with us your experience of your path to diagnosis?

• Can you tell us about what type of treatments you tried and how long and how long it took you to identify the best treatment?

• Can you share more with us about how PsA has affected both your personal and professional life?

• Do you have a message that you'd like to convey to those watching this interview, regarding how they can motivate their patients if a treatment doesn't work and encourage them to try the different recommended treatments, as well as adhere to those treatment?

Alice Gottlieb, MD, Chair of the CME symposium "Time to Think About Both Skin and Joint Disease: Optimizing the Diagnosis and Management of Psoriatic Arthritis" at SBS 2021, shares some clinical pearls about the dermatologist's role in screening and diagnosing psoriatic arthritis, including:

• Can you tell us about screening tools that are currently available for psoriatic arthritis patients?

• What is your personal approach to diagnosing psoriatic arthritis patients?

• What do you feel the dermatologist’s role is in treatment of psoriatic arthritis? Do you have any advice for dermatologists working with rheumatologists as a team approach?

Lawrence Schachner, MD, shares some clinical pearls about treatment of acne and antibiotic stewardship in pediatric patients, including:

• What do dermatologists need to keep in mind when prescribing treatments for pediatric patients with acne?

• How do these new acne treatments address the issue of antibiotic resistance?

• Can you tell us more about the effects of these new acne treatments on the microbiome?

Diane Berson, MD, shares additional clinical pearls on the treatment of acne and antibiotic stewardship, including:

1. Can you discuss how the microbiome is affected in treatment of acne patients?

2. Can you explain which antibiotics are better in terms of resistance?

3. What are the core principles of antibiotic stewardship?

4. What is your personal approach to minimizing antibiotic resistance in acne?

Jonette Keri, MD, shares some highlights about treatment of acne in preteen patients, including:

1. What is your personal approach to treating acne in preteen patients compared to other age groups?

2. What is your advice for dermatologists to keep in mind when treating preteen patients with acne?

3. Can you tell us more about the efficacy and safety of these new acne medications for children and adolescents?

4. How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?

James Del Rosso, DO, discusses new and emerging therapies for treatment of acne patients, including:

1. What is your personal approach for exploring alternative treatments for acne patients beyond first-line therapies?

2. Can you compare the emerging topical treatments for acne?

3. What are some advantages with the newer topical retinoids?

4. How do these new acne treatments address the issue of antibiotic resistance?